Lung Cancer Compact Panel, a Highly Sensitive Multiplex Companion Diagnostic, has been submitted for PMDA approval.

On October 21, 2021, DNA Chip Research Inc. (Ryo Matoba, the president) announced that they have developed a multi-CDx system, a high-sensitivity genetic test to detect abnormal (mutated) DNA in FFPE tissue/Cytology specimens, for targeted therapies of lung cancer. The program, “Lung Cancer Compact Panel Dx Multiplex Companion Diagnostics Test” has been submitted for approval to the concerned Japanese authorities.

>Read More